Proceeding contribution from Kevin Barron (Labour) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
I agree with my hon. Friend. Although the report did not look into the matter in detail, parallel trade and counterfeiting is a problem, not only for the market but for safety and efficacy. It is important that those issues are considered.
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1023
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:35 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285094
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285094
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285094